Multifocals good choice for right patient

Article

Multifocal intraocular lenses (IOLs) are a good choice for the right patient.

Multifocal intraocular lenses (IOLs) are a good choice for the right patient, according to Dr. Martin Leyland of the Royal Berkshire Hospital, presenting the third update of the Cochrane systemic review of multifocal vs. monofocal studies.

All the studies reviewed were randomized controlled trials. "I think there is a problem assessing multifocal lenses because there are two interventions. There is cataract surgery, and these patients tend to be happy with the outcome irrespective of what lens you put in. Then you put the lens in, so for any study to be valid you have to have a control group of monofocal lenses," said Dr Leyland.

Dr Leyland summarized the results 10 RCT studies and found that there was no difference in distance high contrast VA between the two types of lens, while UCVA for near vision was better with the multifocal. It was impossible to compare BCVA for near because the methodology varied so widely between studies. In each of the studies, contrast sensitivity was lower for multifocal IOLs.

"Whether the difference attained statistical sensitivity depended on the size of the study," said Dr Leyland. "But in every trial it was a small difference, much smaller than the 40 to 50%% reduction in contrast you would expect from the optics in a multifocal lens. There must be some sort of post perception processing to compensate for."

For glare and halo, monofocals were significantly better, while multifocal IOLs very significantly reduced spectacle dependence. In 34" of cases, multifocal patients did not need glasses at all.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.